Received Aug 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 93n4j | — |
orofacial mucocutaneous shingle; Orofacial mucocutaneous shingles; This non-serious case was reported by a physician via call center representative and described the occurrence of oral herpes zoster in a female patient who received Herpes zoster (Shingrix) (batch number 93n4j) for prophylaxis. The patient's past medical history included shingles (shingles 1 month before the vaccine). On 16-JUN-2025, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced oral herpes zoster (Verbatim: orofacial mucocutaneous shingle) and facial herpes zoster (Verbatim: Orofacial mucocutaneous shingles). The outcome of the oral herpes zoster and facial herpes zoster were not resolved. It was unknown if the reporter considered the oral herpes zoster and facial herpes zoster to be related to Shingrix. It was unknown if the company considered the oral herpes zoster and facial herpes zoster to be related to Shingrix. Additional Information: GSK receipt date: 30-JUL-2025 Reporter was the HCP (MD) who stated that a patient received her first dose of Shingrix on 16th June 2025. She received the vaccine a month after a case of shingles. The patient now had recurrent orofacial mucocutaneous shingles.
Medical History/Concurrent Conditions: Shingles (shingles 1 month before the vaccine)